|
Name |
H-Leu-his-OH
|
Molecular Formula | C12H20N4O3 | |
IUPAC Name* |
(2S)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoic acid
|
|
SMILES |
CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N
|
|
InChI |
InChI=1S/C12H20N4O3/c1-7(2)3-9(13)11(17)16-10(12(18)19)4-8-5-14-6-15-8/h5-7,9-10H,3-4,13H2,1-2H3,(H,14,15)(H,16,17)(H,18,19)/t9-,10-/m0/s1
|
|
InChIKey |
XWOBNBRUDDUEEY-UWVGGRQHSA-N
|
|
Synonyms |
H-LEU-HIS-OH; Leu-His; 38062-72-5; L-leucyl-L-histidine; Leucyl-Histidine; CHEBI:74539; L-Leu-L-His; L-Leucyl-L-Histidin; CHEMBL1229090; SCHEMBL10583281; SCHEMBL21828702; LH; ZINC1589379; MFCD00037854; AKOS010421083; Q27144716; (2S)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoic acid
|
|
CAS | NA | |
PubChem CID | 6992828 | |
ChEMBL ID | CHEMBL1229090 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 268.31 | ALogp: | -2.2 |
HBD: | 4 | HBA: | 5 |
Rotatable Bonds: | 7 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 121.0 | Aromatic Rings: | 1 |
Heavy Atoms: | 19 | QED Weighted: | 0.567 |
Caco-2 Permeability: | -5.703 | MDCK Permeability: | 0.00000939 |
Pgp-inhibitor: | 0.001 | Pgp-substrate: | 0.403 |
Human Intestinal Absorption (HIA): | 0.014 | 20% Bioavailability (F20%): | 0.002 |
30% Bioavailability (F30%): | 0.002 |
Blood-Brain-Barrier Penetration (BBB): | 0.899 | Plasma Protein Binding (PPB): | 5.53% |
Volume Distribution (VD): | 0.39 | Fu: | 91.71% |
CYP1A2-inhibitor: | 0.013 | CYP1A2-substrate: | 0.105 |
CYP2C19-inhibitor: | 0.061 | CYP2C19-substrate: | 0.058 |
CYP2C9-inhibitor: | 0.015 | CYP2C9-substrate: | 0.619 |
CYP2D6-inhibitor: | 0.013 | CYP2D6-substrate: | 0.051 |
CYP3A4-inhibitor: | 0.195 | CYP3A4-substrate: | 0.062 |
Clearance (CL): | 4.425 | Half-life (T1/2): | 0.919 |
hERG Blockers: | 0.058 | Human Hepatotoxicity (H-HT): | 0.089 |
Drug-inuced Liver Injury (DILI): | 0.048 | AMES Toxicity: | 0.007 |
Rat Oral Acute Toxicity: | 0.258 | Maximum Recommended Daily Dose: | 0.037 |
Skin Sensitization: | 0.266 | Carcinogencity: | 0.021 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.027 |
Respiratory Toxicity: | 0.062 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC001065 | 0.583 | D0RA5Q | 0.429 | ||||
ENC000138 | 0.500 | D07WXE | 0.348 | ||||
ENC002451 | 0.483 | D09NYU | 0.333 | ||||
ENC001904 | 0.417 | D08BTB | 0.305 | ||||
ENC000918 | 0.403 | D0SH3I | 0.303 | ||||
ENC001514 | 0.351 | D04USC | 0.298 | ||||
ENC000749 | 0.310 | D0N4EC | 0.297 | ||||
ENC000717 | 0.296 | D06PSS | 0.278 | ||||
ENC002789 | 0.288 | D00WUF | 0.274 | ||||
ENC002873 | 0.284 | D0EN0G | 0.270 |